A series of cardiometabolic-related news items has been observed from Arrowhead Pharmaceuticals, Avaí Bio, Novo Nordisk, and MiniMed. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, Novartis, Aspen Pharmacare, Medtrum, and Hilo. Below, FENIX provides highlights and insights for the respective news items.
Recently, FDA approved Merck’s Lipfendra (enlicitide) as the first oral PCSK9i to treat adults with hypercholesterolemia, including those with HeFH (view label; view approval letter). With Merck poised to challenge established injectables such as Repatha, Praluent, and Leqvio, FENIX has conducted an in-depth Lipfendra label analysis, detailing how it compares to the market incumbents and how it may impact the LDL-C treatment landscape.
A series of cardiometabolic-related news items has been observed by Fangzhou/Novo Nordisk, CMS, Zealand Pharma, and EMA. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Merck, Boehringer Ingelheim, Abbott, Syntis Bio, Oura/Lilly, and Braveheart. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, Gubra, GSK, Fractyl Health, Ascletis Pharma, Rani Therapeutics, and Boehringer Ingelheim. Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: D&D Pharmatech extended its oral obesity research agreement with Pfizer (view article), Dexcom received clearance of its G7 15-Day CGM in Canada (view press release), and Insulet partnered with Calm to provide well-being resources for diabetes management (view press release). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from MiniMed, CSPC Pharmaceutical, Madrigal Pharmaceuticals, and Novo Nordisk. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, Rani Therapeutics/PegBio, and Pfizer. Below, FENIX provides highlights and insight for the respective news items.
A series of cardiometabolic-related news items has been observed by Hengrui, MindRank, Lilly, Endogenex, Ionis/AstraZeneca, and Dr. Reddy’s. Below, FENIX provides highlights and insights for the respective news items.